European Notebook: Tax Inversions; Patent Settlement Fines; Delays To Release of Clinical Data
Executive Summary
The pursuit of mid-sized European pharma by U.S. firms for tax as well as other benefits continued in July, while biotechs in the region stayed cautious about IPOs; the European Commission encountered opposition to its stance on patent settlements, while EMA had to delay starting the pro-active release of clinical trial data.
You may also be interested in...
Teva Slapped With €60m Fine Over Unlawful EU Provigil Delay
Teva received a “package of commercial side-deals” for agreeing to halt generic competition to Cephalon’s Provigil (modafinil) throughout the EU, which it “would not have achieved without committing to staying out of the market,” according to findings by the European Commission.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.